Roche acquires Seattle-based Stratos in bid to achieve sequencing ambitions

By staff writers

May 22, 2020 -- Roche Diagnostics is set to acquire Seattle-based Stratos Genomics in a deal it said will help advance its ambitions in DNA-based sequencing.

Roche is developing a nanopore sequencer and said that the acquisition of Stratos "complements development" of its nanopore technology, which is aimed at providing usable DNA-based information to individuals for making healthcare decisions.

"The acquisition provides Roche access to Stratos Genomics' unique chemistry, Sequencing by Expansion (SBX)," Roche said in a statement. "The Roche nanopore sequencer, once developed, will [utilize] a novel approach that combines electronic and biological components to sequence DNA for fast, flexible and cost-effective clinical diagnostic testing."

Stratos plans to stay put in Seattle. Financial terms of the deal were not disclosed.

Roche has a long-term strategy to retain its lead in the IVD market by ensuring it stays ahead in high-growth areas. Nanopore sequencing produces richer, long reads and is thought to be more accurate and cost-effective. The company invested up to $15 million in Stratos in 2014.

Oxford Nanopore sends sequencers to China for coronavirus
Oxford Nanopore Technologies has shipped an additional 200 MinION sequencers and related consumables to China to support the ongoing surveillance of the...

Copyright © 2020

Last Updated np 5/22/2020 5:25:21 PM

Register below for our weekly Letter from the Editor to receive the latest Clinical Lab news and insights.